CytoSorbents Corporation · NASDAQ:CTSO
CytoSorbents — FY2014 Earnings Presentation
39 slides from CytoSorbents's earnings presentation, Mar 31, 2015
Slide 1: CytoSorbents Corporation Year 2014 Earnings Call
CytoSorbents Corporation NASDAQ CM: CTSO An Emerging Leader in Critical Care Immunotherapy Year 2014 Earnings Call March 31, 2015
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents, Inc (now known as CytoSorbents Medical Inc) and CytoSorbents Europe GmbH that are not historical facts are forward-looking statements and are subject to risks and unc
Slide 3: CytoSorbents is Well-Positioned as a Leader in Critical Care Immunotherapy
CytoSorbents is Well-Positioned as A Leader in Critical Care Immunotherapy Leading the Prevention or Treatment of Life-Threatening Inflammation in the ICU and Cardiac Surgery using CytoSorb® Blood Purification 3
Slide 4: 2014: A Strong Year of Growth
2014: A Strong Year of Growth 4
Slide 5: Achieved 2014 CytoSorb Sales of $3.1M
Achieved 2014 CytoSorb Sales of $3.1M Driven by a growing combination of Direct Sales, Independent Distributor Sales, and Strategic Partner Sales WMC IntensivMed LLC 5
Slide 6: 2nd CytoSorb Germany User's Meeting
2nd CytoSorb Germany User’s Meeting 6
Slide 7: 1st International CytoSorb User's Meeting
1st International CytoSorb User’s Meeting 7
Slide 8: ISICEM 2015
ISICEM 2015 i Bee Working to Save Lives Through Blood Purification
Slide 9: More Published Case Reports & Studies
More Published Case Reports & Studies 9
Slide 10: Launched International CytoSorb Registry
Launched International CytoSorb Registry • The home of 40+ planned investigator initiated studies with many already enrolling 10
Slide 11: Launched New CytoSorb Website
Launched New CytoSorb Website www.cytosorb.com 11
Slide 12: Partnered with Global Leaders
Partnered with Global Leaders 12
Slide 13: Expansion of Biocon Partnership
Expansion of Biocon Partnership • According to Biocon, hundreds of patients have benefited from CytoSorb® therapy and orders continue to increase • Expanded agreement beyond sepsis to all critical care applications and cardiac surgery with a focus on the systemic inflammatory response syndrome (SIRS
Slide 14: Fresenius Medical Care
Fresenius Medical Care • Entered into a 6 country partnership with Fresenius, the largest dialysis company in the world for exclusive distribution of CytoSorb® in critical care in France, Sweden, Norway, Finland, Denmark and Poland • Leveraging Fresenius’ #1 or #2 position in critical care in these
Slide 15: Cardiac Surgery Initial Partnership
Cardiac Surgery Initial Partnership • Entered into an initial partnership with a top-four global medical device company in cardiac surgery to use CytoSorb® intra-operatively during cardiac surgery in France • Initial evaluation phase expected to be complete in Q2 2015 • Following a successful evalua
Slide 16: Focus on Generating Clinical Data
Focus on Generating Clinical Data 16
Slide 17: FDA Approval of IDE for REFRESH Study
FDA Approval of IDE for REFRESH Study • REFRESH (Reduction in FREe Hemoglobin) Trial is a 20-patient multi-center feasibility study evaluating the safety of CytoSorb use intra-operatively in a bypass circuit in a heart-lung machine during complex cardiac surgery as a means of reducing plasma-free he
Slide 18: Infrastructure to Drive Clinical Data
Infrastructure to Drive Clinical Data Chief SVP of Clinical Medical Development Officer Cardiac Sepsis Trauma Surgery Advisory Advisory Advisory Board Board Board Clinical Trial Manager Director of European Statistician Medical Director United States Trials Scientific Affairs US Air Force 50+ Pivota
Slide 19: Increased Investor Awareness
Increased Investor Awareness 19
Slide 20: NASDAQ Capital Market Listed
NASDAQ Capital Market Listed CytoSorbents (CTSO) Up-listed to NASDAQ in December 2014 • Average daily trading volume: 200K shares ($3M daily trading value) vs 30,000 prior to up-listing 20
Slide 21: #11 on Forbes Best Performing Stocks of 2014
#11 on Forbes Best Performing Stocks of 2014 CytoSorbents Achieved Strong Stock Performance in 2014 comparing favorably to peers 21
Slide 22: Continued Positive Analyst Coverage and Investor Outreach
Continued Positive Analyst Coverage and Investor Outreach 22
Slide 23: Increased Media Coverage
‘By Varun ‘Saxena FlerceDrugbelivery December 24, 2014 staring 1od8V Increased Media Coverage +MAS DEVICE MEDICAL DEVICE DAILY THE DAILY MEDICAL TECHNOLOGY NEWS SOURCE i) eytosorbents inks deal with Fresenius Medical Care (04) ory By Mark Holmer ‘Mass Devicr. ‘December 16, 2044 People in the News: M
Slide 24: Operating and Financial Highlights
Operating and Financial Highlights 24
Slide 25: 2014 Comparative Revenue Results
2014 Comparative Revenue Results 2014 2013 % Incr. Product revenue $ 3,135,387 $ 821,787 282% Grant and other income 987,438 1,600,880 (38)% Total revenue $ 4,122,825 $ 2,422,667 70% • Achieved record CytoSorb® annual sales of $3.1 M, a 282% increase over $822K in 2013. • Grant and other income decl
Slide 26: Rapidly-Growing Year-Over-Year Product Sales
Rapidly-Growing Year-Over-Year Product Sales $3,500,000 $3,135,387 CytoSorb® Product Sales $3,000,000 $600,000 $570,000 $2,500,000 CytoSorb® Product Sales $500,000 Quarter over quarter growth rate has averaged 65% in the last three quarters $2,000,000 $400,000 $314,159 $300,000 $1,500,000 $203,561 $
Slide 27: Quarterly Product Sales
Quarterly Product Sales $1,200,000 CytoSorb® Product Sales $1,031,761 $1,000,000 $871,150 $800,000 $663,233 $600,000 $569,243 $400,000 $314,159 $203,561 $176,098 $200,000 $127,969 $87,960 $13,679 $0 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 • Q4 2014 Product Rev
Slide 28: Product Sales Trends Remain Strong
Product Sales Trends Remain Strong $4,000,000 Trailing Twelve Month Product Sales $3,500,000 $3,135,387 $3,000,000 Trend Line $2,578,396 $2,500,000 $2,000,000 $1,750,196 $1,500,000 $1,214,932 $1,000,000 $821,787 $595,588 $500,000 $405,706 $310,779 $151,574 $- Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013
Slide 29: Balance Sheet and Cap Table
Balance Sheet and Cap Table Consolidated Balance Sheet Data: 12/31/2014 Cash and Short-Term Investments $ 5,549,827 * Total Assets $ 8,468,625 Total Debt $ - Total Shareholder's Equity $ 3,963,183 * * Does not relfect an additional $10.3M financing completed in January 2015. CytoSorbents Cap Table (
Slide 30: Outlook for 2015
Outlook for 2015 med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 31: $20 Billion Opportunity in Critical Care
$20 Billion Opportunity in Critical Care Millions of people are admitted to the intensive care unit in hospitals in the U.S. and the European Union each year with deadly inflammatory conditions Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical • In these conditions, massive inflammation
Slide 32: CytoSorb Removes the Fuel to the Fire
CytoSorb® Removes the Fuel to the Fire • CytoSorb® represents a powerful immunotherapy to control inflammation • Approved in the European Union as the only specifically approved cytokine filter • Clinically proven to remove key cytokines in the blood of critically-ill patients • Approved for use in
Slide 33: Goal: To Prevent or Treat Organ Failure
Goal: To Prevent or Treat Organ Failure Improve Decrease Patient Costs Of Outcome ICU and and Patient Survival Care Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine 33
Slide 34: CytoSorbents Has Tremendous Potential
CytoSorbents Has Tremendous Potential ® CytoSorb may help revolutionize critical care medicine, saving lives, and reducing costs • Massive untapped $20 billion unmet, medical need in critical care • CytoSorb® sales are generating significant growth with attractive 65% gross margins • Continued geogr
Slide 35: Near Term Challenges
Near Term Challenges med CVtOSorbents forking to Save Lives Through Blood Purification
Slide 36: Sales Infrastructure Targets For 2014
Sales Infrastructure Targets For 2014 2013 Targets for 2014 Direct Sales Distributors Partners Direct Sales Distributors Partners 5 Distributors Germany Germany (UK, Ireland, 10+ 2+ Austria Biocon (India) Netherlands, Austria Distributors Partners Switzerland Turkey, Russia) Switzerland 4 sales reps
Slide 37: Restructuring Targets For 2015
Restructuring Targets For 2015 Q1 2015 Targets for 2015 Direct Sales Distributors Partners Direct Sales Distributors Partners Germany Biocon Germany 12 or more ----------- Fresenius 5 or more 8 Distributors Distributors Austria Global Cardiac Austria Partners total total Switzerland Surgery Co. Swit
Slide 38: Q1 2015 Revenue Guidance
Q1 2015 Revenue Guidance • In general, our product sales are too dependent on the timing and size of orders and cannot yet be accurately predicted • We have given guidance, however, when data from the full quarter is known • Expect that Q1 2015 CytoSorb product revenue will be in the range of $700,0
Slide 39: Q&A Session
Q&A Session CytoSorbents Corporation NASDAQ CM: CTSO Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 [email protected] An Emerging Leader in Critical Care Immunotherapy 39